Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2004;109:e331
doi: 10.1161/01.CIR.0000132588.63901.C1
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nishikimi, T.
Right arrow Articles by Whooley, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nishikimi, T.
Right arrow Articles by Whooley, M. A.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Related Collections
Right arrow Other diagnostic testing

(Circulation. 2004;109:e331.)
© 2004 American Heart Association, Inc.


Correspondence

Are Plasma Levels of Atrial Natriuretic Peptide, N-Terminal ProANP, and Brain Natriuretic Peptide Affected by the Presence of Coronary Artery Disease?

Toshio Nishikimi, MD, PhD; Hiroaki Matsuoka, MD, PhD

Department of Hypertension and Cardiorenal Medicine, Dokkyo University Medical School, Mibu, Tochigi, Japan

To the Editor:

We read with great interest the recent article by Bibbins-Domingo et al1 on plasma brain natriuretic peptide (BNP) in outpatients with stable coronary disease. They concluded that elevated levels of BNP are independently associated with inducible ischemia in outpatients with stable coronary disease, particularly among those who have a history of myocardial infarction.

Previous studies have demonstrated that transient myocardial ischemia stimulates the secretion of atrial natriuretic peptide (ANP) and N-terminal ProANP (N-ANP); because of its longer half-life, N-ANP may be a better marker than ANP for the detection of high-grade coronary artery stenosis.2–4 However, whether plasma BNP levels are increased in patients with coronary artery stenosis who have normal left ventricular function remains unknown. To examine whether coronary artery stenosis affects plasma ANP, N-ANP, and BNP levels, we recently measured these peptide levels in 104 patients with normal left ventricular systolic function who had a suspected diagnosis of angina pectoris.5

Plasma levels of all 3 of these natriuretic peptides were higher in patients with coronary artery stenosis (major coronary artery stenosis >75%) (n=65) than in those without stenosis (n=39), whereas hemodynamic variables were similar. Multiple logistic regression analysis revealed that N-ANP (per 100 fmol/mL increase; odds ratio=1.9 [95% CI=1.2 to 2.6], P<0.01), but not ANP (per 10 pg/mL increase; odds ratio=0.9 [95% CI=0.5 to 1.2], P=0.41) or BNP (per 10 pg/mL increase; odds ratio=1.1 [95% CI=0.8 to 1.4], P=0.73), was independently associated with coronary artery stenosis after adjusting for clinical and demographic variables. Furthermore, we measured these natriuretic peptides before and 3 to 6 months after percutaneous coronary intervention in patients with myocardial infarction of recent onset (n=58). Plasma levels of ANP, N-ANP, and BNP significantly decreased in patients without restenosis (n=46) (ANP, 91±15 to 39±7 pg/mL; BNP, 134±28.9 to 41±9 pg/mL; N-ANP, 688±81 to 407±52 fmol/mL; all P<0.05).

In contrast, these natriuretic peptide levels did not change after coronary intervention in patients with restenosis (n=12) (ANP, 57±19 to 50±20; BNP, 102±35 to 57±13; N-ANP, 567±178 to 508±126; all NS). Our results support the findings of Bibbins-Domingo et al1; however, we propose that N-ANP may be more useful for the discrimination of clinically significant coronary artery stenosis than BNP because of its different sites of production, mechanisms of release, and metabolic characteristics.

References

  1. Bibbins-Domingo K, Ansari M, Schiller NB, et al. B-type natriuretic peptide and ischemia in patients with stable coronary disease: data from the Heart and Soul study. Circulation. 2003; 108: 2987–2992.[Abstract/Free Full Text]
  2. Gill JS, Prasad K, Stewart JT, et al. Acute changes in atrial natriuretic peptide, insulin-like growth factor-1, and lactate levels during left anterior descending coronary artery angioplasty. Am Heart J. 1995; 130: 717–722.[CrossRef][Medline] [Order article via Infotrieve]
  3. Malatino LS, Leonardi C, Stancanelli B, et al. Transient myocardial ischemia stimulates atrial natriuretic factor release. Am Heart J. 1992; 123: 693–698.[CrossRef][Medline] [Order article via Infotrieve]
  4. Prachar H, Ogris E, Dittel M, et al. Rapid changes of atrial natriuretic peptide concentration during percutaneous transluminal coronary angioplasty. Am Heart J. 1991; 122: 157–163.[CrossRef][Medline] [Order article via Infotrieve]
  5. Nishikimi T, Mori Y, Ishimura K, et al. Association of plasma atrial natriuretic peptide, N-terminal proatrial natriuretic peptide, and brain natriuretic peptide levels with coronary artery stenosis in patients with normal left ventricular systolic function. Am J Med. 2004; 116: 517–523.[CrossRef][Medline] [Order article via Infotrieve]

 

Response

Kirsten Bibbins-Domingo, PhD, MD; Maria Ansari, MD; Nelson B. Schiller, MD; Barry Massie, MD; Mary A. Whooley, MD

Departments of Medicine and Epidemiology, University of California, San Francisco, Veterans Affairs Medical Center, San Francisco, Calif

We thank Dr Nishikimi and colleagues for describing the results of their study demonstrating an association between N-terminal pro-atrial natriuretic peptide (N-ANP)—but not atrial natriuretic peptide (ANP) or brain natriuretic peptide (BNP)—and coronary artery stenosis. The authors conclude that N-ANP may be more useful than BNP for discriminating clinically significant coronary artery stenosis. We are pleased that their independent study supports an association between natriuretic peptides and coronary disease. However, we note that the authors’ study examined a different outcome (coronary stenosis) than our study (inducible ischemia). Because anatomic findings often do not correlate with severity of ischemia or risk of acute coronary syndromes,1 the association of N-ANP with coronary stenosis does not necessarily imply that N-ANP is more useful for discriminating clinically significant coronary disease than BNP. Moreover, the authors found similar declines in ANP, N-ANP, and BNP in patients after post-MI percutaneous interventions, suggesting that all 3 peptides are associated with ischemia. Regardless of potential differences between ANP, N-ANP, and BNP, results from both of these studies suggest a potential mechanism for the increased risk of future cardiac events associated with elevations in natriuretic peptides2,3 and may explain why tests for natriuretic peptides are not specific for ventricular dysfunction among patients with coronary disease.4,5

References

  1. Ambrose JA, Tannenbaum MA, Alexopoulos D, et al. Angiographic progression of coronary artery disease and the development of myocardial infarction. J Am Coll Cardiol. 1988; 12: 56–62.[Abstract]
  2. de Lemos JA, Morrow DA, Bentley JH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med. 2001; 345: 1014–1021.[Abstract/Free Full Text]
  3. Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med. 2004; 350: 655–663.[Abstract/Free Full Text]
  4. Bibbins-Domingo K, Ansari M, Schiller NB, et al. B-type natriuretic peptide and ischemia in patients with stable coronary disease: data from the Heart and Soul study. Circulation. 2003; 108: 2987–2992.[Abstract/Free Full Text]
  5. Bibbins-Domingo K, Ansari M, Schiller NB, et al. Is B-type natriuretic peptide a useful screening test for ventricular dysfunction in patients with coronary disease? The Heart and Soul Study. Am J Med. 2004; 116: 509–516.[CrossRef][Medline] [Order article via Infotrieve]



This article has been cited by other articles:


Home page
CirculationHome page
L. B. Nielsen, J. P. Goetze, T. Nishikimi, and H. Matsuoka
Response
Circulation, January 18, 2005; 111(2): e15 - e16.
[Full Text]


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nishikimi, T.
Right arrow Articles by Whooley, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nishikimi, T.
Right arrow Articles by Whooley, M. A.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Related Collections
Right arrow Other diagnostic testing